Results 251 to 260 of about 5,265,871 (311)
Most-Favored-Nation pricing meets Joint Clinical Assessment: early evidence of compounding pressure on European drug launches. [PDF]
Ramagopalan SV, Ryan ML.
europepmc +1 more source
ABSTRACT Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation.
Matthieu Mahévas +4 more
wiley +1 more source
Orphan Designation for Drugs Approved in the United States and European Union: A Comparative Analysis. [PDF]
Costa E, Ross JS, Kesselheim AS.
europepmc +1 more source
NOR1 loss relates to inflammation and biological ageing in multiple sclerosis motor cortex. [PDF]
Unlu Kobya B +3 more
europepmc +1 more source
Reframing the value of reserve antibiotics: how ultra-orphan reimbursement pathways could offer fair and equitable access to new antibiotics. [PDF]
Quinn J +10 more
europepmc +1 more source
Orphan GPCRs in diabetes mellitus: metabolic control, inflammation, and drug development. [PDF]
Chandrabose S +5 more
europepmc +1 more source
Rare disease patients protection: theoretical discussion and institutional construction of orphan drug designation in China. [PDF]
Zhao X, Zhang M, Zhang M.
europepmc +1 more source

